MedTrace Logo

Neoadjuvant Treatment Modalities in Esophageal Cancer

NCT04821843 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2026-01-21

No results posted yet for this study

Summary

Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.

Conditions

  • Esophageal Cancer
  • Chemotherapy Effect
  • Chemoradiation
  • Surgery
  • Targeted Therapy
  • Immunotherapy
  • Esophagogastric Juction Cancer

Interventions

PROCEDURE

Surgery

Radical esophagectomy

DRUG

Immunotherapy

Anti-PD-1/PD-L1 Antibody

DRUG

5-FU Analog based chemotherpay

W1-5 qW or d1-14, q3W according to physician's preference

DRUG

Nimotuzumab

200-400mg, d1,qW

DRUG

Platinum based chemotherapy

q1-3W according to physician's preference

DRUG

Paclitaxel based chemotherapy

q1-3W according to physician's preference

RADIATION

Radiotherpay

40-50Gy/1.8-2.2Gy/20-25f

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04821843 on ClinicalTrials.gov